Related Experiment Videos
Comparison between two non-halogenated glucocorticoid ointments in psoriasis
The Journal of International Medical Research
|January 1, 1981
Summary
Budesonide demonstrated superior therapeutic effects compared to hydrocortisone-17-butyrate (HCB) in treating psoriasis. This controlled study highlights budesonide
Area of Science:
- Dermatology
- Pharmacology
Background:
- Topical steroids are a cornerstone in psoriasis management.
- Non-halogenated topical steroids offer an alternative with potentially improved safety profiles.
- Nordic classification categorizes topical steroids based on potency and efficacy.
Purpose of the Study:
- To compare the therapeutic efficacy of two non-halogenated topical steroids: budesonide and hydrocortisone-17-butyrate (HCB).
- To evaluate the classification of these steroids based on observed clinical outcomes in psoriasis patients.
Main Methods:
- A controlled, double-blind investigation was conducted.
- Thirty-six patients diagnosed with psoriasis participated in the study.
- Two non-halogenated topical steroid ointments were administered and their effects observed.
Main Results:
- Budesonide exhibited a good therapeutic effect in all patients studied.
- Hydrocortisone-17-butyrate (HCB) was consistently less effective than budesonide.
- A clear difference in therapeutic effect was observed between budesonide and HCB.
Conclusions:
- Budesonide and HCB belong to different topical steroid groups based on Nordic classification.
- Budesonide demonstrates superior efficacy for psoriasis treatment compared to HCB.
- Findings support the differential efficacy within non-halogenated topical steroid classes.